americanpharmaceuticalreviewAugust 11, 2021
ADMA Biologics Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the commercial availability of additional vial sizes of BIVIGAM and NABI-HB, which are currently in stock and commercially available to U.S healthcare providers and patients.
“The availability of these additional NABI-HB and BIVIGAM vial sizes meaningfully enhances ADMA’s go-to-market offering for its commercial Immune Globulin (“IG”) product portfolio and allows for more versatile utilization by providers and patients,” said Adam Grossman, President and Chief Executive Officer of ADMA. “We anticipate the broader suite of BIVIGAM and NABI-HB vial configurations will help in providing more targeted dosing levels, minimize drug wastage and allow ADMA’s IG products to have vial presentations in line with competitor offerings. These new vial sizes, which further advance the Company’s mission to differentiate through its hands-on approach to manufacturing and developing plasma-derived therapeutics, represent yet another important milestone achieved by ADMA’s regulatory, commercial and supply chain teams. We look forward to increasing market penetration with our complete portfolio of IG and hyperimmune globulin products to better serve the growing needs of U.S. patients and physicians in the periods ahead.”
NABI-HB 1 mL and 5 mL vial sizes are available to U.S. healthcare providers and patients and, at the present time, ADMA expects continuous supply availability of both vial sizes going forward.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: